TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* completed 12 weeks treatment in the preceding pivotal study ATL1251/038/CL~Exclusion Criteria:~* Subjects who are pregnant or breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.~* Clinical diagnosis of Parkinson's disease.~* Able to refrain from any Parkinson's disease medication not permitted by the protocol.~Exclusion Criteria:~* Female of childbearing potential~* History or presence of atypical Parkinsonian syndrome.~* History of surgical intervention for Parkinson's disease.~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Any condition possibly affecting drug absorption.~* Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- PF-06649751 low dose (1 mg QD) (Type: EXPERIMENTAL): PF-06649751 low dose level (1 mg QD)
- PF-06649751 middle dose 1 (3 mg QD) (Type: EXPERIMENTAL): PF-06649751 lower middle dose 1 (3 mg QD)
- PF-06649751 middle dose 2 (7 mg QD) (Type: EXPERIMENTAL): PF-06649751 higher middle dose 2 (7 mg QD)
- PF-06649751 high dose (15 mg QD) (Type: EXPERIMENTAL): PF-06649751 high dose (15 mg QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~To be eligible to participate in this study, a subject must satisfy all of the following criteria:~1. The subject must be a healthy adult aged 18-65 years, and weighing at least 50 kg.~2, The subject must have normal renal function (creatinine \<1.5 mg/dL; \<1 plus proteinuria); normal hepatic function (bilirubin \< 1.5 mg/dL); normal hematologic function (WBC greater than or equal to 2500/mm(3); granulocytes greater than or equal to 1200/mm(3); platelets greater than or equal to 120,000; hematocrit greater than or equal to 38).~3. A female of childbearing potential may be entered if she is using 1 or 2 forms of effective contraception (depending on the type of contraception), and has a negative serum pregnancy test within 1 week of beginning G-CSF administration. She must continue with the effective contraception 3 months after receiving plerixafor~4. The subject must be willing to allow blood cell samples to be stored.~EXCLUSION CRITERIA:~A subject will be ineligible to participate in this study if any of the following criteria are met:~1. The subject has a temperature \> 38 degrees Celsius, or WBC \> 9000/mm(3).~2. A female who is pregnant or lactating as determined by history and/or pregnancy test.~3. The subject has a history of vasculitis, uncontrolled hypertension, or symptomatic coronary artery disease, or similar disorders.~4. The subject has a positive test result for any of the following: human immunodeficiency virus (HIV) I \& II antibody, hepatitis C virus (HCV) antibody, hepatitis B soluble antigen (HBSAg), or the rapid plasma reagin (RPR) test for syphilis.~5. The subject lacks peripheral venous access in arm veins adequate for apheresis.~6. The subject is currently participating in other research studies.~7. The subject may be excluded at the discretion of the Principal Investigator (PI).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: None): Any healthy volunteers that are eligible to donate blood.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification and MF stage should have never met the criteria for stage IIA or higher in the patient medical history~* Lesions cover less than 80% of BSA~* Age ≥ 18~* ECOG/WHO performance status 0-2~Exclusion Criteria:~* Previous treatment with CL gel~* Concurrent or planned local or systemic anti-CTCL therapy~* Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment~* Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult patients with early stage MF-CTCL (stage IA-IB) (Type: EXPERIMENTAL): Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age.~* ° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained \> 7 days. Episodes of AF which are terminated by electrical or pharmacologic cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes.~  * Planned to undergo first catheter ablation procedure ( prior atrial flutter typical is allowed)~* Ability to understand the requirements of the study and sign the informed consent form.~* Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements~* Projected lifespan greater than 1 year~Exclusion Criteria:~* They have baseline prolonged QT or renal failure precluding safe used of ibutilide~* Rheumatic heart disease,~* Current intra-cardiac thrombus,~* History of MI or CABG within 6 weeks;~* Class IV HF,~* Unable to sign consent~* Projected lifespan of \< 1 year~* Women known to be pregnant or to have positive beta-HCG.~* Participation in another study that would interfere with this study.~* Unstable Angina~* Recent cerebral ischemic events~* Contraindication to anticoagulation~* Prior history of polymorphic ventricular tachycardia or torsades de pointes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with AF (Type: EXPERIMENTAL): Patients with AF and planned to undergo first catheter procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with the same regimen including 3 HAART from at least 4 months~* Aged 18 years or older~* Who gave informed consent to the participation to the study~* With at least two viral load \< 50 copies/mL in two consecutive determinations at least 6 months apart (tolerance of two weeks)~* With CD4 cell count \> 200 cells/μL and absence of any opportunistic infection or AIDS-related disease for at least one year prior to the screening.~* With R5 tropism by viral DNA genotyping (geno2pheno clonal)~* With CD4 cell count nadir\>50 cell/mmc or 100 cell/mmc if previous enfuvirtide or integrase inhibitors use~Exclusion Criteria:~* With at least one major or two minor mutation conferring resistance to darunavir reported in the update list of International AIDS Society - USA , in previous resistance test~* Previous D/M or X4 viral tropism~* Previous major clinical toxicities (grade \>=3) to the proposed drugs of the study~* Pregnancy or breast feeding, desire of pregnancy in the short term~* Past exposure to Chemokine Receptor 5 antagonist~* HBsAg serostatus~* Liver cirrhosis of class C (Child-Pugh)~* Sulpha drug hypersensitivity~* The presence of major non AIDS-defining diseases that, in the opinion of the investigator, may compromise the retention of the patient in the study for the necessary follow-up period.~* Estimated glomerular filtration \< 30 ml/min (cockroft-Gaut; MDRD formula if black-African or african-american) at screening visit~* Hypertransaminasemia of grade IV (more than 10 times the upper normal limit) at screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MARAVIROC, DARUNAVIR/r (Type: EXPERIMENTAL): Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy
- current ART with 3 drugs (Type: SHAM_COMPARATOR): Patients on HAART with three drugs and HIV RNA below 50 copies/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of moderate to severe plaque-type psoriasis and have had participated in Study P05319.~* Subjects must have demonstrated an adequate but suboptimal response to infliximab in Study P05319~* Subjects must be at least 18 years old~* Subjects must be candidates for phototherapy or systemic treatment for psoriasis.~* Subjects must not be pregnant and must meet contraceptive requirements~* Subjects must meet tuberculosis screening criteria~* Subjects must meet laboratory and medical history screening requirements~Exclusion Criteria:~* Subjects for whom infliximab or methotrexate is contraindicated or not recommended.~* Subjects already using certain investigational, biological, or immunosuppressive drugs~* Subjects with certain comorbid conditions~* Subjects who currently have or have a history of certain infections~* Subjects who have recently received live virus or bacterial vaccinations~* Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IFX q 6 weeks (Type: EXPERIMENTAL): None
- IFX + MTX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Nexfin Cardiac Output in Elderly Patients With Hip Fracture

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged over 80~* Able to give their own informed consent~Exclusion Criteria:~* Severe valvular heart disease~* Taking lithium

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of small bowel bacterial overgrowth or irritable bowel syndrome and who are undergoing routine colonoscopies or subjects who are undergoing routine colonoscopy and test positive for small bowel bacterial overgrowth will be candidates. If the patient has prior lactulose breath test done for clinical purposes then repeat lactulose breath test will not be required. If no prior lactulose breath test has been performed then it will be done as part of this research study. In addition patients who test negative for SBBO will be candidates for the control population.~Exclusion Criteria:~* Medications-Subjects on any medication that could affect the ileocecal valve high-pressure zone will be excluded; this includes use of prokinetic agents, current use of any antibiotics and anticholinergics. Patients will be excluded if the lactulose breath test is done on antibiotics or during the colonoscopy preparation.~GI symptoms, conditions and disorders: In addition exclusion criteria will include a history of ileocecal resection or disease affecting the colon and/or small bowel including crohn's disease, ulcerative colitis or diseases causing diarrhea.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Normal volunteers (Type: None): Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
- Irritable bowel syndrome (Type: None): Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received~* HER-2 overexpression 2+ or 3+ using IHC or FISH +~* Measurable disease~* At least one prior chemotherapy regimen~* Not in a prior irradiation field~* No patients with brain metastatic disease who has not been irradiated or uncontrolled brain metastatic disease after irradiation~* No more than 25% of myeloproductive bone marrow irradiated. More than 4 weeks since prior radiotherapy and recovered~* Age 18 - 75 year old~* Performance status (WHO) 0-2~* Life expectancy more than 12 weeks~* Absolute neutrophil count \> 1500/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (bilirubin \< 2 mg/dL, SGOT/SGPT \< 2 times upper limit of normal, ALP \< 3 times upper limit of normal, creatinine \< 1.5 upper limit of normal~* Adequate cardiac function (LVEF \> 50%)~Exclusion Criteria:~* Pregnant or nursing~* Positive pregnancy test~* Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce P-450 cytochrome~* Motor or sensory neuropathy \> grade 1 according to NCIC toxicity criteria~* History of allergic reaction attributed to docetaxel~* Psychiatric illness or social situation that would preclude study compliance~* Other concurrent uncontrolled illness~* Other invasive malignancy within the past 5 years except cured basal cell skin carcinoma and cervical carcinoma in situ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): GHer
- 2 (Type: EXPERIMENTAL): CapHer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Fish or Meat Consumption in Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>65 years with a first hip fracture who have a reasonable high chance of returning to their homes after rehabilitation,~* with a sufficient cognitive function to understand the objectives of the study~* the ability to go / walk without support of a person prior to the hip fracture.~* the life expectancy should be more than 6 months.~* the ability to use the provided food and willingness to participate~* sign the informed consent.~Exclusion Criteria:~* Patients are excluded who will probably not return to their home but to a nursing home.~* Patients who lack the cognitive function to understand the study objectives~* Patients with a missing informed consent~* Patients with reduced life expectancy of less than 6 months.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fish intervention (Type: EXPERIMENTAL): The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
- Meat control group (Type: NO_INTERVENTION): The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Being in nursing home since 1 month and above~* Aged \> 65 years old~* Subjects agree to participate at this project~Exclusion criteria :~* Antecedent of atrial fibrillation

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- electrocardiogram (Type: EXPERIMENTAL): Patient will take an electrocardiogram in order to detect atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Only men will be included since this is a study of post prostatectomy incontinence. Cases will be comprised of men who are post radical retropubic or laparoscopic (robotic) prostatectomy who have stress urinary incontinence based on history and a minimum of 50 grams of urine loss on 24 hour pad weights. Controls will be comprised of men who are post radical retropubic or laparoscopic (robotic) prostatectomy who do not have any kind or amount of incontinence based on history. Cases and controls will be matched for both age and race these have been shown to alter anatomical appearance of structures and lower urinary tract function.~Exclusion Criteria:~* Criteria for both groups include urge incontinence, urinary retention, neurologic disease, insulin dependent diabetes, high dose steroid use, pre-surgical abnormal voiding function or incontinence, prior pelvic radiation or urologic surgery, any prior incontinence surgery, current medical therapy for incontinence or a perineal route of radical prostatectomy since this had been shown to give a distinctly different appearance on MRI compared to the laparoscopic or retropubic approach. Any patient with pelvic or systemic recurrence of their prostate cancer will also be excluded. Any man with relative or absolute contraindications to MRI such as implants or claustrophobia will be excluded.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Continent Men (Type: None): None
- Incontinent Men (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility